Comparison of Clinical Outcomes of Intravitreal Bevacizumab and Aflibercept in Type 1 Prethreshold Retinopathy of Prematurity in Posterior Zone II.

Eftekhari Milani, Amir; Bagheri, Masood; Niyousha, Mohamad Reza; Rezaei, Leila; Hazeri, Somayyeh; Safarpoor, Samad; Abdollahi, Maryam

Eftekhari Milani, Amir; Bagheri, Masood; Niyousha, Mohamad Reza; Rezaei, Leila; Hazeri, Somayyeh; Safarpoor, Samad; Abdollahi, Maryam.

Afiliación

Eftekhari Milani A; Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Bagheri M; Department of Ophthalmology, Imam Khomeini Eye Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Niyousha MR; Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Rezaei L; Department of Ophthalmology, Imam Khomeini Eye Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Hazeri S; Department of Biology, Corcordia University, Montreal, Canada.
Safarpoor S; Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abdollahi M; Department of Ophthalmology, Nikookari Eye Center, Tabriz University of Medical Sciences, Tabriz, Iran.

J Curr Ophthalmol ; 34(1): 87-92, 2022.

Article en En | MEDLINE | ID: mdl-35620366

Palabras clave

Aflibercept; Anti-vascular endothelial growth factor; Bevacizumab; Retinopathy of prematurity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Risk_factors_studies Idioma: En Revista: J Curr Ophthalmol Año: 2022 Tipo del documento: Article País de afiliación: Irán

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google